This site is intended for healthcare professionals

account_circleSign in
Go to /sign-in page

You can view 5 more pages before signing in

Docetaxel

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Docetaxel is a taxoid which is indicated for the treatment of:

  • ovarian cancer resistant to platinum-based chemotherapy
  • prostate cancer - is recommended, within its licensed indications, as a treatment option for men with hormone-refractory metastatic prostate cancer only if their Karnofsky performance-status score is 60% or more (1)
  • breast cancer resistant to first line treatment such as anthracyline
    • docetaxel (given with doxorubicin and cyclophosphamide) is recommended as a possible adjuvant treatment for women with early node-positive breast cancer (2)

Reference:

  1. NICE (June 2006). Docetaxel for the treatment of hormone-refractory metastatic prostate cancer.
  2. NICE (September 2006). Docetaxel for the adjuvant treatment of early node-positive breast cancer

Related pages

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page